Hematology: activated partial thromboplastin time (APTT) in Dogs (Canis) | Vetlexicon
canis - Articles

Hematology: activated partial thromboplastin time (APTT)

ISSN 2398-2942

Contributor(s) :


Synonym(s): aPTT, PTT, Partial thromboplastin time, (Kaolin-cephalin clotting time)

Overview

  • Evaluating intrinsic (XII, XI, IX, VIII) plus common (X,V, II, I) pathways help determine whether bleeding is due to one or more defects in coagulation (secondary hemostasis), from other causes (eg trauma, ulceration, neoplasia) or possibly primary disorders (like von Willebrand's disease). 

Uses

Alone

  • Evaluation of intrinsic (surface induced) and common pathways in the clotting cascade. 

In combination

Other points

  • Half lives for the various factors vary with mammalian species and are unknown exactly but from human extrapolation, likely of the order of hours (factor VII) to days, averaging 1-2 days.  
  • Functional detection of deficiencies in factors VIII (Hemophilia A) and IX (Factor IX/ Hemophilia B) more commonly and clinically significant, even fatal. However, XII, XI, V, X, II, I and/or prekallikrein are also being evaluated. Individual deficiencies are estimated though to be <30% for detection (ie prolongation in the time). 
  • Alternatively but more crudely assessed via whole blood clotting time or activated clotting time  Hematology: activated clotting time, but levels of clotting factor then estimated at <5-10% normal. 
  • More dynamic testing (eg thromboelastography Thromboelastography (TEG)) is now, albeit less widely, available and more accurately describes the clotting cascade including hypercoagulable states.  
  • If APTT is significantly prolonged, specific factor assaying can then be performed (sequentially) using breed reported risk or commoner deficiencies initially (eg factor VIII / anti-hemophilic factor).  
  • Inherited factor deficiency can be sex-linked, the mutation found on the X chromosome (eg VIII, IX) and so a male phenotypic disease. Others (eg II, VII, XII are more complex autosomal diseases with variable penetrance. 
  • Separate genetic mutational tests are available for many inherited traits in specific breeds where the genetic cause/location is known. 

Sampling

Subscribe To View

This article is available to subscribers.

Try a free trial today or contact us for more information.

Tests

Methodologies

Manual, optical, electrical or electromagnetic  

  • A. Citrated plasma is incubated with surface activator (eg Kaolin) and procoagulant phospholipids (eg cephaloplastins, partial thromboplastin) at 37°C (e.g water bath, heating block or cuvette/cup). 
  • B. Calcium ions (factor IV) are added (counter-acting the citrate chelation) and the solutions-plasma mixed. 
  • C. Time taken for fibrin to then form is measured (eg visible fibrin/gel-clot, light transmission (spectro-) or scatter (nephro-), electrode voltage difference, oscillating magnetized ball). 
  • D. Testing (especially manual) is often performed in duplicate with an average value reported.  

Availability

  • Varied bench top automated analyzers available for in house (mainly PT, APTT and/or ACT) 
  • Most clinical pathology laboratories offer a basic hemostatic/clotting profile  Hematology: complete blood count (CBC), coagulation times (PT and APTT) and possibly fibrin degradation products (FDP) Fibrin degradation products or D-dimers Hematology: D-dimers.   
  • Individual factor assays typically require sending to specific referral labs. 

Validity

Sensitivity

  • More sensitive than activated clotting time (ACT) Hematology: activated clotting time
  • Still relatively insensitive since activity of clotting factor must be <30% to result in abnormal elevation. However, this may correlate well with clinically evident bleeding. 

Specificity

  • Does not require presence of blood’s cellular components (eg platelets). 
  • Varies with method and potential in vitro factors as listed.  

Technique intrinsic limitations

  • Some manual methods or automated instrument platforms are designed for human testing, so less suitable for canine specimens (faster clot formation relatively). The instrument and method should be validated for each specific species and canine specimens. 
  • Reference intervals are often poorly defined and data on healthy sampling conditions may not translate to patients with systemic diseases or if on anti-coagulant therapy.  

Result Data

Subscribe To View

This article is available to subscribers.

Try a free trial today or contact us for more information.

Further Reading

Publications

Refereed papers

  • Recent references from VetMedResource and PubMed.
  • Couto C J (1999) Clinical approach to the bleeding dog or cat. Vet Med 450-459.
  • Sheafer S E & Couto C J (1999) Clinical approach to a dog with anticoagulant rodenticide poisoning. Vet Med 466-471.
  • O'Brien S R, Teresa, Sellers T, Meyer D (1995) Artifactual Prolongation of the Activated Partial Thromboplastin Time Associated With Hemoconcentration in Dogs. JVIM 3, 169-170 Wiley

Other sources of information